drugset / Trial / NCT05347095

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095

Phase 3 Active not recruiting 288 enrolled Janssen-Cilag Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.

Timeline

Start
2022-09-27
Primary completion
2027-03-25
Completion
2027-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Subcutaneous